A clinical study of adenovirus mediated Reduced Expression in Immortalized Cells/Dickkopf-3 (REIC/Dkk-3) gene therapy for malignant pleural mesothelioma.
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2018
Price : $35 *
At a glance
- Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- 26 Sep 2018 Results (n=13) presented at the 19th World Conference on Lung Cancer
- 29 Sep 2016 Status changed from recruiting to discontinued.
- 18 Apr 2015 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network.